title: Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy.
abstract: BACKGROUND
  The release kinetics of copeptin in patients with acute myocardial infarction (AMI) have been difficult to establish.
  
  
  METHODS
  We analyzed the release kinetics of copeptin in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ablation of septal hypertrophy (TASH) as a model of AMI. We included 21 consecutive patients who underwent TASH. Blood samples were collected before and at 15, 30, 45, 60, 75, 90, and 105 min, and at 2, 4, 8, and 24 h after TASH. Serum copeptin was quantified by a sandwich immunoluminometric assay.
  
  
  RESULTS
  All patients had copeptin concentrations below the 99th percentile at baseline. The median copeptin concentration was significantly increased at 30 min [16.0 pmol/L; interquartile range (IQR), 13.4-20.2 pmol/L], compared with the median baseline concentration (6.6 pmol/L; IQR, 5.3-8.3 pmol/L; P = 0.002). The copeptin concentration peaked 90 min after induction of myocardial infarction and returned to baseline concentrations (median, 8.2 pmol/L; IQR, 6.3-10.1) after 24 h, compared with the above baseline values (P = 0.06). Serum creatine kinase (CK) activities were significantly increased above baseline values by 1 day after TASH [median maximal postprocedural CK activity, 935.0 U/L (IQR, 545.5-1115.0 U/L); median baseline CK activity, 80.0 U/L (IQR, 63.5-109.0 U/L); P < 0.001].
  
  
  CONCLUSIONS
  Our results provide additional evidence that early rule-out of suspected AMI is possible by using the copeptin concentration in combination with cardiac troponin T.
authors.affiliation: Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany. c.liebetrau@kerckhoff-klinik.de
authors.forename: Christoph
authors.initials: C
authors.lastname: Liebetrau
authors.forename: Holger
authors.initials: H
authors.lastname: Nef
authors.forename: Sebastian
authors.initials: S
authors.lastname: Szardien
authors.forename: Oliver
authors.initials: O
authors.lastname: Dörr
authors.forename: Matthias
authors.initials: M
authors.lastname: Willmer
authors.forename: Sandra
authors.initials: S
authors.lastname: Voss
authors.forename: Christian
authors.initials: C
authors.lastname: Troidl
authors.forename: Jedrzej
authors.initials: J
authors.lastname: Hoffmann
authors.forename: Johannes
authors.initials: J
authors.lastname: Rixe
authors.forename: Andreas
authors.initials: A
authors.lastname: Rolf
authors.forename: Christian
authors.initials: C
authors.lastname: Hamm
authors.forename: Helge
authors.initials: H
authors.lastname: Möllmann
mesh_terms: D055011:Ablation Techniques; D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000097:blood* / Q000601:surgery*; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006020:Glycopeptides / Q000097:blood*; D006346:Heart Septum / Q000473:pathology / Q000601:surgery*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*
chemical_list: D006020:Glycopeptides; C048197:copeptins; D003402:Creatine Kinase